[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-386765-105":59,"doc-detail-386765-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","major-clinical-research-advances-in-gynecologic-cancer-in-2022-highlight-on-late-line-parp-inhibitor-withdrawal-in-ovarian-cancer-ariel-4-impact-solo-3","Major clinical research advances in gynecologic cancer in 2022 - highlight on late-line PARP inhibitor withdrawal in ovarian cancer - ARIEL-4 impact - SOLO-3","","In the 2022 series, major clinical research advances in gynecologic oncology were summarized based on the Asian Society of Gynecologic Oncology Review Course. The review covered ovarian cancer long-term follow-up data, new PARP inhibitors, overall survival issues in PARP inhibitor monotherapy, hyperthermic intraperitoneal chemotherapy, immunotherapy, and antibody-drug conjugates. Cervical cancer topics included surgery and treatments across locally advanced, advanced, metastatic, and recurrent settings, while corpus cancer included follow-up regimens and targeted immune and pathway inhibitors. A special note focused on PARP inhibitor market withdrawal for heavily pretreated ovarian cancer due to increased death risk concerns from ARIEL-4 and SOLO-3 final results.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/major-clinical-research-advances-in-gynecologic-cancer-in-2022-highlight-on-late-line-parp-inhibitor-withdrawal-in-ovarian-cancer-ariel-4-impact-solo-3/386765/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/major-clinical-research-advances-in-gynecologic-cancer-in-2022-highlight-on-late-line-parp-inhibitor-withdrawal-in-ovarian-cancer-ariel-4-impact-solo-3/386765.png","ImageObject",300,407,{"name":92,"@type":93},"moss~","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What key ovarian cancer topics were included in the 2022 review?","Question",{"text":112,"@type":113},"The review covered long-term follow-up data, new PARP inhibitors, overall survival issues in PARP inhibitor monotherapy, hyperthermic intraperitoneal chemotherapy, immunotherapy, and antibody-drug conjugate approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which aspects of cervical cancer treatment were summarized?",{"text":117,"@type":113},"It summarized surgery in early-stage disease and therapies for locally advanced, advanced, metastatic, or recurrent settings.",{"name":119,"@type":110,"acceptedAnswer":120},"Why was withdrawal of PARP inhibitors highlighted for heavily pretreated ovarian cancer patients?",{"text":121,"@type":113},"The article emphasized withdrawal based on ARIEL-4 and SOLO-3 final overall survival results, citing concerns about increased risk of death.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},386765,1790699759,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","J Gynecol Oncol. 2023 Mar;34(2):e51 [https://doi.org/10.3802/jgo.2023.34.e51](https://doi.org/10.3802/jgo.2023.34.e51)[ ](https://doi.org/10.3802/jgo.2023.34.e51)pISSN 2005-0380·eISSN 2005-0399  \nReview Article  \nReceived: Jan 31, 2023  \nRevised: Feb 20, 2023  \nAccepted: Feb 23, 2023  \nPublished online: Mar 2, 2023  \nCorrespondence to  \nDong Hoon Suh  \nDepartment of Obstetrics and Gynecology, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam 13620, Korea.  \nEmail: [sdhwcj@naver.com](sdhwcj@naver.com)  \n*Jung-Yun Lee, Yoo-Young Lee, and Jeong-Yeol Park contributed equally to this work.  \n© 2023. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ([https://](https://)[ ](https://)[creativecommons.org/licenses/by-nc/4.0/](creativecommons.org/licenses/by-nc/4.0/)) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.  \nORCID iDs  \nJung-Yun Lee  [https://orcid.org/0000-0001-7948-1350](https://orcid.org/0000-0001-7948-1350)[ ](https://orcid.org/0000-0001-7948-1350)[Yoo-Young Lee](Yoo-Young Lee)  [https://orcid.org/0000-0001-5902-9877](https://orcid.org/0000-0001-5902-9877)[ ](https://orcid.org/0000-0001-5902-9877)[Jeong-Yeol Park](Jeong-Yeol Park)  [https://orcid.org/0000-0003-2475-7123](https://orcid.org/0000-0003-2475-7123)[ ](https://orcid.org/0000-0003-2475-7123)[Seung-Hyuk Shim](Seung-Hyuk Shim)  [https://orcid.org/0000-0001-8043-2257](https://orcid.org/0000-0001-8043-2257)[ ](https://orcid.org/0000-0001-8043-2257)Se Ik Kim  [https://orcid.org/0000-0002-9790-6735](https://orcid.org/0000-0002-9790-6735)[ ](https://orcid.org/0000-0002-9790-6735)[Tae-Wook Kong](Tae-Wook Kong)  [https://orcid.org/0000-0002-9007-565X](https://orcid.org/0000-0002-9007-565X)  \nMajor clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3  \nJung-Yun Lee ,1,* Yoo-Young Lee ,2,* Jeong-Yeol Park ,3,* Seung-Hyuk Shim ,4 Se Ik Kim ,5 Tae-Wook Kong ,6 Chul Kwon Lim ,7 Hyun Woong Cho ,8 Dong Hoon Suh  9  \n1Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, Korea 2Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea  \n3Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea  \n4Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea  \n5Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea 6Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea 7Department of Obstetrics and Gynecology, Eulji Medical Center, Eulji University School of Medicine, Daejeon, Korea  \n8Department of Obstetrics and Gynecology, Guro Hospital, Korea University College of Medicine, Seoul, Korea  \n9Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea  \nABSTRACT  \nIn the 2022 series, we summarized the major clinical research advances in gynecologic oncology based on communications at the conference of Asian Society of Gynecologic Oncology Review Course. The review consisted of 1) Ovarian cancer: long-term follow-up data, new poly (ADP-ribose) polymerase (PARP) inhibitors, overall survival (OS) issues with PARP inhibitor monotherapy, hyperthermic intraperitoneal chemotherapy, immunotherapy, and antibody-drug conjugate; 2) Cervical cancer: surgery in early stage disease, therapy for locally advanced stage and advanced, metastatic, or recurrent setting; and 3) Corpus cancer: follow-up regimen, immune checkpoint inhibitor, WEE1 inhibi","cbCaid5AuyupRkLA","https://ap.wps.com/l/cbCaid5AuyupRkLA","pdf",4678064,26,"English","# Abstract\n## Ovarian cancer advances\n## Cervical cancer advances\n## Corpus cancer advances\n## Note on PARP inhibitor withdrawal (ARIEL-4, SOLO-3)","[{\"question\":\"What key ovarian cancer topics were included in the 2022 review?\",\"answer\":\"The review covered long-term follow-up data, new PARP inhibitors, overall survival issues in PARP inhibitor monotherapy, hyperthermic intraperitoneal chemotherapy, immunotherapy, and antibody-drug conjugate approaches.\"},{\"question\":\"Which aspects of cervical cancer treatment were summarized?\",\"answer\":\"It summarized surgery in early-stage disease and therapies for locally advanced, advanced, metastatic, or recurrent settings.\"},{\"question\":\"Why was withdrawal of PARP inhibitors highlighted for heavily pretreated ovarian cancer patients?\",\"answer\":\"The article emphasized withdrawal based on ARIEL-4 and SOLO-3 final overall survival results, citing concerns about increased risk of death.\"}]","Major clinical research advances in gynecologic cancer in 2022 - highlight on late-line PARP inhibitor withdrawal in ovarian cancer - ARIEL-4 impact - SOLO-3 | PDF",1790275719,66]